Gemcitabine Plus Platinum Combination Chemotherapy for Elderly Patients with Advanced Non-small Cell Lung Cancer: A Retrospective Analysis
Cancer Research and Treatment 2011³â 43±Ç 4È£ p.217 ~ p.224
Àü»óÈÆ(Chun Sang-Hoon) - Catholic University School of Medicine Department of Internal Medicine Division of Oncology
ÀÌÁöÀº(Lee Ji-Eun) - Catholic University School of Medicine Department of Internal Medicine Division of Oncology
¹Ú¹ÌÈñ(Park Mi-Hee) - Catholic University School of Medicine Department of Internal Medicine Division of Oncology
°ÁøÇü(Kang Jin-Hyoung) - Catholic University School of Medicine Department of Internal Medicine Division of Oncology
±è¿µ±Õ(Kim Young-Kyoon) - Catholic University School of Medicine Department of Internal Medicine Division of Pulmonology
¿Õ¿µÇÊ(Wang Young-Pil) - Catholic University School of Medicine Department of Chest Surgery
¹ÚÀç±æ(Park Jae-Kil) - Catholic University School of Medicine Department of Chest Surgery
±èÈƱ³(Kim Hoon-Kyo) - Catholic University School of Medicine Department of Internal Medicine Division of Oncology
Abstract
Purpose: This study aimed to analyze the efficacy and toxicity of gemcitabine plus platinum chemotherapy for patients aged 70 years or older with advanced non-small-cell lung cancer (NSCLC).
Materials and Methods : We reviewed the records of stage IIIB, IV NSCLC patients or surgically inoperable stage II, IIIA NSCLC patients who were aged 70 years or older when treated with gemcitabine (1,250 mg/m2) plus cisplatin (75 mg/m2) or carboplatin (AUC5) chemotherapy from 2001 to 2010 at Seoul St. Mary¡¯s Hospital, Uijeongbu St. Mary¡¯s Hospital and St. Vincent¡¯s Hospital. Gemcitabine was administered on days 1 and 8, and cisplatin or carboplatin was administered on day 1. Treatments were repeated every 3 weeks for a maximum of 4 cycles.
Results: The median age of the 62 patients was 73.5 years (range, 70 to 84 years). Forty-one (66%) patients exhibited comorbidity. The mean number of treatment cycles was 3.9. The compared average relative dose intensity of gemcitabine plus platinum chemotherapy was 84.8%. The median progression-free survival and overall survival (OS) were 5.0 months and 9.4 months, respectively. Reduced Eastern Cooperative Oncology Group (ECOG) performance status (none vs. ¡Ã1) and weight loss (<5% vs. ¡Ã5%) after treatment were found to have a significant effect on OS (p=0.01).
Conclusion: Gemcitabine plus platinum chemotherapy is an effective treatment option with an acceptable level of toxicity in patients aged 70 years or older with good performance status in advanced NSCLC.
Å°¿öµå
Non-small-cell lung carcinoma, Aged, Gemcitabine, Platinum, Drug therapy
KMID :
0939920110430040217
¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸
µîÀçÀú³Î Á¤º¸
À¯È¿¼º°á°ú(Recomendation)
Gemcitabine plus platinum chemotherapy is an effective treatment option with an acceptable level of toxicity in patients aged 70 years or older with good performance status in advanced NSCLC. The median progression-free survival and overall survival (OS) were 5.0 months and 9.4 months.